Phase II Study of Proteasome Inhibitor Bortezomib in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

2004526 citationsJournal Articlebronze Open Access

Authors

André Goy · The University of Texas MD Anderson Cancer Center

Anas Younes · Millennium Engineering and Integration (United States)

Peter McLaughlin · The University of Texas MD Anderson Cancer Center

Barbara Pro · Hygeia Hospital

Jorge Romaguera · Millennium Engineering and Integration (United States)

Frederick Hagemeister · Hygeia Hospital

Luis Fayad

Abstract

Bortezomib showed promising activity in relapsed mantle-cell lymphoma and encouraging results in other B-cell lymphomas. Future studies will explore bortezomib in combination with other cytotoxic or biologic agents.

Topics & Keywords

Lymphoma Diagnosis and Treatment Chronic Lymphocytic Leukemia Research Ubiquitin and proteasome pathways

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 23, Issue 4, pp. 667-675

DOI: 10.1200/jco.2005.03.108

Field-Weighted Citation Impact: 31.54